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What concentration of tranexamic acid is needed to inhibit
fibrinolysis? A systematic review of pharmacodynamics
studies
Roberto Picettia, Haleema Shakur-Stilla, Robert L. Medcalfb,
Joseph F. Standingc and Ian Robertsa
Intravenous tranexamic acid (TXA) reduces death because
of bleeding in patients with trauma and postpartum
haemorrhage. However, in some settings intravenous
injection is not feasible. To find different routes of
administration, we first need to determine the minimal
concentration of TXA in the blood that is required to inhibit
fibrinolysis.
We conducted a systematic review of in-vitro and in-vivo
pharmacodynamics studies. We searched MEDLINE,
EMBASE, OviSP, and ISI Web of Science from database
inception to November 2017 for all in-vitro (including
simulated clotting models) or in-vivo studies reporting the
relationship between the TXA concentration in blood or
plasma and any reliable measure of fibrinolysis.
We found 21 studies of which 20 were in vitro and onewas in
vivo. Most in-vitro studies stimulated fibrinolysis with tissue
plasminogen activator and measured fibrinolysis using
viscoelastic, optical density, or immunological assays. TXA
concentrations between 10 and 15mg/l resulted in
substantial inhibition of fibrinolysis, although concentrations
between 5 and 10mg/l were partly inhibitory.
TXA concentrations of 10–15mg/l may be suitable targets
for pharmacokinetic studies, although TXA concentrations
above 5mg/l may also be effective. Blood Coagul
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Introduction
Tranexamic acid (TXA) reduces bleeding by inhibiting
the enzymatic breakdown of fibrin blood clots (fibrinoly-
sis) [1]. Plasminogen produced by the liver is converted
into the fibrinolytic enzyme plasmin by tissue plasmino-
gen activator (tPA). Plasminogen and tPA bind to C-
terminal lysine residues on fibrin leading to localized
plasmin formation and fibrin cleavage [2]. TXA is a
molecular analogue of lysine that inhibits fibrinolysis
by competing with fibrin for the lysine-binding sites in
plasminogen. TXA inhibits the capacity of plasminogen
and plasmin to bind to fibrin, hence preserving blood
clots from plasmin-mediated lysis [1].
Intravenous administration of TXA safely reduces death
because of bleeding in patients with trauma and postpar-
tum haemorrhage (PPH) [3–5]. In both situations, most
deaths occur soon after bleeding onset and treatment
delay reduces the survival benefit [6]. It is imperative that
patients are treated urgently. TXA is inexpensive, widely
available, and heat stable. It is cost effective in sub-
Saharan Africa and Southern Asia, where most haemor-
rhagic deaths occur [7]. Nevertheless, because of long
distances to healthcare facilities and a lack of emergency
transport many patients are not treated soon enough.
One of the barriers to rapid treatment is the need for an
intravenous injection. Health workers able to insert intra-
venous lines may be unavailable in rural areas and even
when they are, securing intravenous access can be diffi-
cult in shocked patients with collapsed veins. Although
TXA is available for oral and intravenous use, there has
been little research into different routes of administra-
tion. Intramuscular injection would be easier and would
require less training than IV use.
To determine the minimal plasma level of TXA needed
to inhibit fibrinolysis, and hence identify whether oral or
intramuscular injection would be a viable treatment
option, we conducted a systematic review of pharmaco-
dynamics studies. We reviewed in-vivo and in-vitro stud-
ies reporting both the concentration of TXA in blood or
plasma and its effects on any reliable measure of fibrino-
lysis. This work will inform future studies into the
bioavailability of TXA after oral, intramuscular, and
subcutaneous administration.
Review article 1
0957-5235 Copyright  2018 The Author(s). Published by Wolters Kluwer Health, Inc. DOI:10.1097/MBC.0000000000000789
Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on
the journal’s website (www.bloodcoagulation.com).
This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any
medium, provided the original work is properly cited.
Methods
The systematic review methods were published in
advance of data collection on the PROSPERO register
(protocol number CRD42017079646). The review is
reported in accordance with PRISMA guidelines [8].
Inclusion criteria
Types of studies: In-vitro and in-vivo studies reporting
the effects of TXA on fibrinolysis in human blood,
plasma, or simulated clotting models.
Methods tomeasureTXA in the blood and plasma include
HPLC, liquid chromatography–mass spectrometry, gas
chromatography, or paper electrophoresis [9–11].
Eligible fibrinolysis assays included:
Whole blood tests. These assess fibrinolysis in the pres-
ence of platelets and blood cells.
Thromboelastography (TEG) and rotational thromboe-
lastometry (ROTEM) measure the viscoelastic proper-
ties of blood during clot formation and fibrinolysis in vitro.
Comparisons with biochemical assays (e.g., plasmin–
antiplasmin complexes) suggest that they may be insen-
sitive to low-grade hyperfibrinolysis [12,13].
The halo assay is a high throughput method that involves
forming halo-shaped, tissue factor-induced blood clots in
96 well plates and measuring fibrinolysis using a spectro-
photometer [14].
Global fibrinolytic capacity involves measuring fibrin
degradation products by ELISA in clotted-lysing blood.
Global fibrinolytic capacity is estimated after correcting
for background fibrin degradation products in parallel
blood samples incubated with the direct plasmin inhibi-
tor, aprotinin. Because no activators are used, endoge-
nous fibrinolysis is assessed [15,16].
Plasma tests: A limitation of these tests is that platelets,
cells, and some proteins are absent [14].
The overall fibrinolytic potential and global fibrinolytic
potential of plasma is assessed by measuring plasma
turbidity in a spectrophotometer after addition of tPA
[16]. The initiation of coagulation and subsequent fibri-
nolysis change the optical density of the plasma. Other
optical assays include the clot formation and lysis (Clo-
FAL) assay [16,17] and the clot lysis assay (for example,
as described by Niego et al. [18]).
ELISA and other immunoassays measure specific fibri-
nolytic markers such as D-dimer [17,19]. D-dimer can be
measured by ELISA (quantitative), whole blood aggluti-
nation (qualitative), or latex bead agglutination (quanti-
tative or qualitative). Results from different assays are not
comparable and false positives can result from other
factors influencing D-dimer levels [17,19].
To facilitate comparisons, concentrations of tPA were
converted to ng/ml using the following formula:
10 000 IU/ml¼ 20 000 ng/ml¼ 300 nM [20]. Similarly,
urokinase-type plasminogen activator (uPA) concentra-
tions were converted to ng/ml with the following formula:
3200 IU/ml¼ 20 000 ng/ml¼ 380 nM [21].
Types of participants
Studies on blood from healthy volunteers or patients.
Animal studies were excluded because the concentration
needed to inhibit fibrinolysis may be different from
humans [22,23]. Animal (e.g., murine) plasma clots are
known to be more resistant to lysis with human tPA [24].
Types of interventions
TXA is added to blood, plasma, or clotting models in vitro
or given by any route (in vivo).
Types of outcomes
Concentration of TXA (mg/l) needed to reduce fibrino-
lytic activity to a clinically significant level, for example,
80% reduction in activity [9], or 95% maximal effective
concentration (EC95) [25].
Search
We searched MEDLINE, EMBASE, OviSP, and the ISI
Web of Science from the date of database inception to 6
November 2017 using the following terms and keywords:
TXA, amino methyl carboxylic acid, amino methyl cyclo-
hexane acid, cyklokapron, pharmacodynamics, pharma-
cokinetics, blood, plasma, human, fibrinolysis, fibrin,
fibrinogen, antifibrinolytic, antifibrinolysis, clot, lysis,
turbidity, immunoassay, immunochemistry, TEG,
ROTEM, intravenous, oral, intramuscular, dose, dosing,
concentration, and haemorrhage (see Appendix for
detailed search strategy, http://links.lww.com/BCF/
A58). Truncation symbols were used with the text words,
when appropriate, to capture variations in spelling and
word endings. We also examined the references of sys-
tematic reviews located during the search and performed
a forward search with the eligible studies to identify
further potential articles.
Study selection
Two reviewers independently assessed records to deter-
mine whether they met the inclusion criteria. Titles and
abstracts were screened and the full texts of any poten-
tially relevant reports were assessed for inclusion. Two
reviewers independently assessed the full texts to con-
firm eligibility. Disagreements between reviewers were
resolved by consensus.
Data extraction
Data were extracted into a prespecified table including:
method to detect TXA in blood or plasma, protocol for
TXA administration or addition, fibrinolytic assay used,
outcome of fibrinolysis assay, and TXA concentration
that achieved a significant reduction of fibrinolysis.
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Data synthesis
The results of each study were described with no math-
ematical synthesis of results. We examined graphically
the relationship between the concentration of tPA used to
stimulate fibrinolysis and the minimal inhibitory TXA
concentration (80% inhibition of fibrinolysis) and calcu-
lated a regression line with 95% confidence intervals
(95% CI). The regression was calculated with Stata
statistical software: Release 15 (College Station, Texas,
USA).
Results
We found 369 potentially eligible records. After screen-
ing titles and abstracts we reviewed the full text of 35
records. We found 21 studies meeting the inclusion
criteria (Fig. 1), one of which was unpublished [personal
communication]. The first study was published in 1968.
All studies were published in English.
The results are shown in Tables 1 and 2. We found 20 in-
vitro and one in-vivo study. There were 16 in-vitro
studies in which TXA was added to blood or plasma
drawn from healthy volunteers or commercial sources,
and four studies using clotting models or fibrin plates.
One clinical trial measured TXA levels and fibrinolysis in
blood from surgical patients.
In-vitro studies
In most studies, fibrinolysis was stimulated with tPA
(Table 1).
Andersson et al. [9] incubated fibrin plates with tissue
homogenates containing tPAs and measured the effect of
TXA concentrations up to 100mg/l. Fibrinolysis (lysed
area on plate) was reduced by 98% with 100mg/l TXA,
90% with 25mg/l TXA and 80% with 10mg/l TXA.
Dai et al. [26] used tPA to stimulate fibrinolysis in plasma
from haemophilia patients who had factor VIII antibo-
dies. Clot lysis time was measured using optical methods.
Clot lysis time increased from 6 to 16min with TXA at
5mg/l and from 6 to 37min using 10mg/l.
Dietrich et al. [27] stimulated fibrinolysis in blood (tPA at
200 ng/ml) from healthy volunteers and used ROTEM
(LY60, defined as percentage decrease in clot amplitude
at 60min after maximal amplitude) to assess the effect of
TXA on fibrinolysis. Fifty percentage inhibition [IC50,
median (25th; 75th percentile)] was achieved with TXA
0.43mg/l (0.29, 0.51) and complete inhibition with TXA
1.57mg/l. The authors stimulated fibrinolysis in plasma
(tPA 100 ng/ml) and studied the decrease in optical
density 45min after maximum optical density. Fifty
percentage inhibition (IC50) was achieved with TXA
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Fig. 1
Records idenﬁed through database 
searching n = 457 
Addional records idenﬁed through 
other sources n = 6 
Records screened aer duplicates 
removed n = 369 
Records excluded    
n = 334 
Full-text arcles assessed for 
eligibility n = 35 
Full-text arcles excluded
 n = 14 
Studies included in qualitave 
synthesis n = 21 
Flow diagram of search. Modified with permission [8].
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0.66mg/l (0.48, 0.67). TXA 1.57mg/l decreased fibrino-
lysis to less than 10%.
Dirkman et al. [28] stimulated fibrinolysis in blood with
tPA (100 ng/ml) and evaluated the effect of a single dose
of TXA (330mg/l) corresponding to 2 g/75 kg body
weight using ROTEM. TXA reduced clot lysis at 45
and 60min [clot lysis index (CLI45) and CLI60]. CLI60
(median, 25th/75th percentile) increased from 21% (7%/
59%) without TXA to 90% (89%/92%) with TXA. TXA
330mg/l increased CLI45 from 64% (48/80) to 94% (93/
98) in conditions of moderate acidosis and from 49% (26/
71) to 92% (86.5/94) in severe acidosis [29].
Fears et al. [30] stimulated fibrinolysis in plasma with
anisoylated lys-plasminogen streptokinase activator com-
plex or tPA and measured the lysis time of iodine-radi-
olabelled fibrin clots. TXA at 10mg/l reduced anisoylated
lys-plasminogen streptokinase activator complex -
induced fibrinolysis by 80%. TXA at 157.2mg/l
completely inhibited tPA-induced initiation of fibrinoly-
sis. TXA at 40mg/l caused 80% inhibition at 4 h, TXA at
10mg/l caused 70% inhibition at 1 h and 30% inhibition at
4 h. TXA at 10 and 40mg/l inhibited 34% of ongoing tPA-
induced fibrinogenolysis.
Fletcher et al. [22] used tPA-stimulated plasma and TEG
to calculate the estimated percentage lysis 30min after
maximum clot amplitude. The TXA concentration
needed to inhibit fibrinolysis was 14.7mg/l (95% CI
13.7–15.6).
Godier et al. [31] spiked blood samples with 67 ng/ml,
267 ng/ml, and 1333 ng/ml tPA and studied the effect of
TXA on fibrinolysis using TEG. 67 ng/ml tPA did not
affect the TEG traces but there was a significant effect
with 267 and 1333 ng/ml. With 267 ng/ml tPA, a concen-
tration of 3mg/l TXA partially corrected TEG parame-
ters, whereas 300mg/l TXA corrected most parameters.
With 1333 ng/ml tPA, a concentration of 3mg/l TXA was
ineffective, but 300mg/l TXA corrected LY60 and esti-
mated percentage lysis. The effect of 30mg/l TXA was
similar to that of 300mg/l TXA at all tPA concentrations
(Table 1). TXA also inhibited fibrinogenolysis (based on
the drop in fibrinogen level after tPA addition). Addition
of 67 ng/ml tPA did not cause fibrinogenolysis. However,
tPA resulted in a concentration-dependent fall in fibrin-
ogen levels at 267 and 1333 ng/ml tPA. This fall was
partly prevented by the addition of 3mg/l TXA and
almost fully prevented at a concentration of 30mg/l
or higher.
He et al. [32] spiked normal commercial plasma with tPA
in the presence of a thrombin inhibitor or a factor Xa
inhibitor to mimic an antithrombotic therapy. TXA at
0.4mg/l prolonged the clot lysis time from 40 to 50min
with a thrombin inhibitor and from 25 to 50min with a
factor Xa inhibitor. TXA at 9.5mg/l abolished fibrinolysis
in both cases.
Hoylaerts [33] used tPA in an in-vitro system where wells
of tissue culture plates were coated with iodine-radiola-
belled fibrin. Plasminogen was preincubated with several
TXA concentrations and added to the wells. The radio-
activity released into the solution was the product of the
solubilization of fibrin and was measured for up to
200min. The time required to solubilize 50% of fibrin
was calculated. The solubilization time increased from
100min in the controls to 200min with 2mg/l of TXA.
Kostousov et al. [34] used tPA to induce moderate fibri-
nolysis in blood diluted with Ringer’s lactate (Hospira,
Lake Forest, Illinois, USA) and severe fibrinolysis in
blood diluted with Ringer’s lactate and Voluven (Hos-
pira, Lake Forest, Illinois, USA). Inmoderate fibrinolysis,
TXA at 1 and 2mg/l inhibited TEG clot lysis. In severe
fibrinolysis, TXA 3mg/l decreased LY30 to less than 8%.
Lijnen et al. [35] induced fibrinolysis in plasma with
staphylokinase 30 nM or streptokinase 100 nM. Lysis
time of iodine-radiolabelled fibrin clots was measured.
The concentrations of TXA needed to reduce clot lysis to
50% of the value measured without TXA after 2 h were
0.63mg/l with staphylokinase and 3.14mg/l with strepto-
kinase. In other experiments, TXA was added 30min
after the addition of staphylokinase or 15min after strep-
tokinase. TXA needed to reduce fibrinolysis to 50% after
90min was 2.36mg/l with staphylokinase and 11mg/l
with streptokinase.
Longstaff [36] prepared fibrin clots by mixing fibrinogen
and a-thrombin. Plasmin was added when maximal opti-
cal density was reached and clot lysis measured for 5 h.
Lysis decreased with increasing TXA concentration
(Table 1). Plasminogen activation was also assessed in
a solution with fibrinogen, thrombin, plasminogen, and
tPA. Plasminogen activation dropped to 40% with
7.86mg/l TXA and 20% with 15.72mg/l of TXA. TXA
between 8 and 15mg/l reduced clot lysis (75 and 45%
lysis rate, respectively) and inhibited plasminogen acti-
vation (40 and 20% activation rate, respectively).
Longstaff [unpublished] used ROTEM (maximum clot
firmness, clot lysis index) to measure tPA and uPA-
induced fibrinolysis. TXA 1.57mg/l inhibited fibrinolysis
almost as efficiently as TXA 157.21mg/l with both tPA
and uPA. Longstaff also used the halo assay [14] with
whole blood or plasma. In both cases, 40mg/l of TXA
almost completely inhibited tPA-induced clot lysis and a
concentration almost an order of magnitude lower inhib-
ited uPA-induced lysis (Table 1).
Niego et al. [18] stimulated fibrinolysis in commercial
human plasma with tPA and measured clot turbidity
for 100min. TXA at 15.7mg/l completely inhibited
fibrinolysis.
Okamoto et al. [37] incubated fibrin plates and tested the
inhibitory activity of TXA on fibrinolysis caused by the
human plasma activator of plasminogen. They showed
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that 0.16mg/l of TXA inhibited 50% of fibrinolysis,
1.6mg/l inhibited about 90% of fibrinolysis, and
15.7mg/l inhibited fibrinolysis almost completely.
Rozen et al. [25] used ROTEM to study the effect of
TXA on fibrinolysis in blood from children (aged 1–10
years) undergoing cardiac catheterization for congenital
heart disease (10 cyanotic and 10 noncyanotic) and blood
from healthy adult volunteers. Fibrinolysis was induced
with tPA and the effect of TXA on lysis index at 30min
was assessed. The efficacy concentration 50% (EC50) in
adults was 6.8mg/l (95% CI, 6.4–7.2), and the EC95 was
11.3mg/l (95%CI, 10.6–12.9). In children, EC50 was
2.8mg/l (95%CI, 2.6–3.0) and EC95 was 8.6mg/l
(95%CI, 6.9–14.9).
Sperzel and Huetter [38] spiked plasma with tPA and
assessed fibrinolysis by measuring plasma turbidity in a
spectrophotometer following the addition of tPA. TXA
concentrations ranged from 0.47 to 471.63mg/l. TXA
inhibited fibrinolysis with an IC50 of 3.79 0.17mg/l.
Takada et al. [39] added either 1250 or 6250 ng/ml of
urokinase to plasma and assessed a single dose of TXA
(157.2mg/l) by measuring fibrin and fibrinogen degrada-
tion products. For both concentrations of urokinase, TXA
inhibited fibrinolysis and fibrinogenolysis. TXA was also
tested in a system with plasminogen, thrombin, fibrino-
gen, and urokinase (6250 ng/ml). TXA completely inhib-
ited fibrinolysis and reduced fibrinogenolysis by about
50%.
Yee et al. [40] added tPA to adult plasma and plasma from
cord blood collected at caesarean deliveries of 23 full-
term (38–42 weeks) singleton live births. The effect of
TXA on fibrinolysis was determined with TEG (LY30).
Theminimumdose of TXA needed to completely inhibit
fibrinolysis was 6.54mg/l (95% CI, 5.19–7.91) in neonatal
plasma and 17.5mg/l (95% CI, 14.59–20.41) in
adult plasma.
Figure 2 shows the relationship between the tPA con-
centration used to induce fibrinolysis and the minimal
concentration of TXA needed to inhibit at least 80% of
fibrinolysis. The TXA concentration required increased
by 0.004mg/l for every 1 ng/ml of tPA used to stimulate
fibrinolysis (95% CI 0.001–0.008, R2¼ 47.26%).
In-vivo treatments
Couturier et al. [41] compared the effect of two TXA
dosing schemes with a no TXA group in children under-
going surgery with cardiopulmonary bypass (CPB)
(Table 2). The dosing schemes included a continuous
administration of TXA (10mg/kg bolus dose followed
with a continuous 1mg/kg/h infusion until completion of
surgery, and then 10mg/kg dose in the CPB prime), and a
discontinuous administration (10mg/kg bolus dose, then
a 10mg/kg dose in the CPB prime, and 10mg/kg dose at
the end of CPB). They measured TXA, D-dimer, and
fibrinogen. TXA levels ranged between 28.0 2.3 and
59.9 7.5mg/l (meanSEM) during surgery. TXA
inhibited the bypass-induced D-dimer increase which
peaked at 393 93 ng/ml in the discontinuous group
and 562 165 ng/ml in the continuous group compared
with the no TXA group (2274 474 ng/ml).
Discussion
Although TXA may have other biological effects, this
systematic review aimed to determine the minimum
concentration of TXA necessary to inhibit fibrinolysis
[42,43]. Our results suggest that TXA concentrations
between 10 and 15mg/l provide near maximal inhibition
of fibrinolysis, although concentrations between 5 and
10mg/l provide significant inhibition (e.g., 18, 32). The
minimum TXA concentration might be lower in children
[44].
Despite an extensive search for all eligible studies, pub-
lished or unpublished, it is possible that some studies
were missed. Although less is known about the impact of
publication bias in systematic reviews of pharmacody-
namics studies, than in reviews of clinical trials, selective
reporting has been documented and is a potential threat
to validity [45,46]. Furthermore, many pharmacodynam-
ics studies fail to report aspects of study methodology
(e.g., blinding) that may have a bearing on the results.
Because the rate of fibrinolysis in normal blood or plasma
is slow, fibrinolytic activators are added to speed up the
process. Although differences in the potency of
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Plot showing the tPA concentrations used in in-vitro studies and the
corresponding minimal TXA concentration needed to inhibit at least
80% of fibrinolysis. The regression line with 95% CI is also shown. Five
studies were excluded: three studies that used only one very high
concentration of TXA to inhibit fibrinolysis [28,29,39], one study that
used a concentration of tPA so high [30] that it falls in the range of tPA
levels used in thrombolytic treatment (960–1830 ng/ml [52]), and one
study that did not report the concentration needed for 80% inhibition of
fibrinolysis were excluded [38]. tPA, tissue plasminogen activator; TXA,
tranexamic acid.
fibrinolytic activators make direct comparisons difficult,
our results suggest that the tPA concentration used to
stimulate fibrinolysis influences the results. Indeed, the
wide range of tPA concentrations used may explain the
heterogeneity in inhibitory concentrations. Another
potential limitation is the diversity of the methods used
to measure fibrinolysis. The validation and standardiza-
tion of methods to measure fibrinolysis has progressed
more slowly than for coagulation testing and widely
accepted assays are unavailable.
Can results from in-vitro studies be used to guide the
target TXA concentration for patients with trauma and
PPH? Cohort studies in patients with major trauma show
that plasma tPA concentrations are highest in patients
with hypotension and acidosis. Nevertheless, the tPA
concentrations seen in even the most severely injured
patients are lower than those used to stimulate fibrinoly-
sis in vitro. Indeed, tPA levels in trauma patients are
generally below 100 ng/ml [47–50]. This suggests that
results from in-vitro studies may overestimate the con-
centration of TXA needed to inhibit fibrinolysis in vivo.
In most of the included in-vitro studies, TXA was added
either before tPA was added or at the same time. The
experimental protocol therefore differs from clinical
situations. Only one publication [30] reported the effect
of TXA on ongoing fibrinolysis, adding TXA 15–30min
after stimulating fibrinolysis, but very high doses of
fibrinolysis activators were used (e.g., 80 nM of tPA,
corresponding roughly to more than 5000 ng/ml). For this
reason, the extent to which in-vitro results can be applied
to the clinical practice is open to question.
Urokinase is a fibrinolytic activator sometimes used in in-
vitro experiments. However, clinical studies show that
tPA is involved in the early activation of fibrinolysis with
levels reaching a peak at about 3 h after injury. uPA levels
increase after tPA levels begin to decrease [51]. It is
unlikely that uPA plays a major role in fibrinolysis during
the early stage of trauma or PPH, when TXA is known to
be life saving.
In conclusion, this systematic review suggests that TXA
concentrations in the range of 10–15mg/l result in sub-
stantial inhibition of fibrinolysis. These results will
inform pharmacokinetic studies to examine the bioavail-
ability of TXA after oral, intramuscular, and subcutane-
ous administration. If therapeutic levels of TXA can be
achieved in a timely manner via these alternative routes,
this could have important implications for the prehospital
management of patients with trauma and postpartum
haemorrhage.
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